Adderall: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: A 3:1 mixture of dextra-amphetamine to l-amphetamine is used to treat attention deficit hyperactivity disorder. ==History== In the United States, the mixture was approved ...) |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
A 3:1 mixture of | A 3:1 mixture of dextro-[[amphetamine]] to levo-[[amphetamine]] salts and is used to treat [[attention deficit hyperactivity disorder]]. The brand Adderall® is marketed by [http://www.shire.com/ Shire Pharmaceuticals]. | ||
==History== | ==History== | ||
In the [[United States]], the mixture was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) by the FDA in 1960.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=011522 Drugs@FDA]. U S Food and Drug Administration</ref> The extended release version was approved in 2001.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=021303 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version (not extended release) was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2002.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=040422 Drugs@FDA]. U S Food and Drug Administration</ref> | In the [[United States]], the mixture was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) by the FDA in 1960.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=011522 Drugs@FDA]. U S Food and Drug Administration</ref> The extended release version was approved in 2001.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=021303 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version (not extended release) was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2002.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=040422 Drugs@FDA]. U S Food and Drug Administration</ref> | ||
==Pharmacokinetics== | |||
The time to reach maximum plasma concentration is:<ref name="dailymed-adderallxr">[http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5535 Adderall XR] (Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate and Amphetamine Aspartate) capsule, extended release [Shire US Inc.]</ref> | |||
* Adderall XR® is about 7 hours | |||
* Addreall 3 hours | |||
Adderall XR 20 mg one daily has similar pharmacokinetics to Adderall(immediate-release) 10 mg twice dialy administered 4 hours apart. <ref name="dailymed-adderallxr">[http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5535 Adderall XR] (Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate and Amphetamine Aspartate) capsule, extended release [Shire US Inc.]</ref> | |||
The mean elimination half-life in adults for d-amphetamine is 10 hours and for the l-amphetamine is 13 hours<ref name="dailymed-adderallxr">[http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5535 Adderall XR] (Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate and Amphetamine Aspartate) capsule, extended release [Shire US Inc.]</ref> | |||
==External links== | ==External links== | ||
Revision as of 17:02, 9 November 2009
A 3:1 mixture of dextro-amphetamine to levo-amphetamine salts and is used to treat attention deficit hyperactivity disorder. The brand Adderall® is marketed by Shire Pharmaceuticals.
History
In the United States, the mixture was approved with a New Drug Application (NDA) by the FDA in 1960.[1] The extended release version was approved in 2001.[2] A generic version (not extended release) was approved with a Abbreviated New Drug Application (ANDA) in 2002.[3]
Pharmacokinetics
The time to reach maximum plasma concentration is:[4]
- Adderall XR® is about 7 hours
- Addreall 3 hours
Adderall XR 20 mg one daily has similar pharmacokinetics to Adderall(immediate-release) 10 mg twice dialy administered 4 hours apart. [4]
The mean elimination half-life in adults for d-amphetamine is 10 hours and for the l-amphetamine is 13 hours[4]
External links
The most up-to-date information about Adderall and other drugs can be found at the following sites.
- Adderall - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Adderall - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Adderall - Detailed information from DrugBank.
References
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ 4.0 4.1 4.2 Adderall XR (Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate and Amphetamine Aspartate) capsule, extended release [Shire US Inc.]